## **ACR Open Rheumatology**

Vol. 4, No. 4, April 2022, pp 275 © 2021 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.



DOI 10.1002/acr2.11394





The patient, a 55-year-old man on hemodialysis (HD) (in-center HD three times per week) for 32 years (low-flux HD for 25 years), presented with a 10-year history of progressive deformity of the hands. The patient was diagnosed with  $\beta_2$ -microglobulin amyloidosis, or dialysisrelated amyloidosis (DRA), on the basis of clinical presentation and radiographic findings. Although histological assessment remains the gold standard for DRA, the diagnosis is usually clinical in patients suspected of needing HD and relies on the combination of typical clinical features, such as carpal tunnel syndrome, camptodactyly, and characteristic radiographic findings of multiple rapidly enlarging bone cysts. The bone cysts are radiolucent lesions and frequently have thin sclerotic margins (white arrows). Amyloid deposition along the flexor tendons of the hand leads to irreducible flexion contractures of the fingers (white arrowheads). Besides DRA findings, vascular calcifications, such as arteriosclerosis (red arrows), and a calcified arteriovenous fistula anastomotic aneurysm (red arrowheads) were also present in our patient's radiography. In the past, DRA was nearly a universal finding in patients with an HD vintage of more than 10 years. Also, DRA has been described in patients undergoing peritoneal dialysis and even in patients with chronic kidney disease before the initiation of dialytic therapy. However, the epidemiology of DRA has decreased in the past 20 years because of the use of high-flux membranes that have superior β<sub>2</sub>-microglobulin clearance, ultrapurified water, and more biocompatible membranes that generate less inflammation (1). Apart from enhancing  $\beta_2$ -microglobulin clearance by high-flux HD membranes or kidney transplantation, treatment of DRA is otherwise palliative. The most debilitating aspects of DRA are carpal tunnel syndrome and paraparesis due to epidural β<sub>2</sub>-microglobulin amyloid deposition. Moreover, DRA has been shown to predispose to pathologic fractures due to bone cysts in rare cases (2). Analgesics may help with periarticular and bone pain (3).

276 STEFAN AND STANCU

- Portales-Castillo I, Yee J, Tanaka H, Fenves AZ. β-2 microglobulin amyloidosis: past, present, and future. Kidney360 2020;1:1447–55.
- Campistol JM, Solé M, Muñoz-Gómez J, Riba J, Ramón R, Revert L. Pathological fractures in patients who have amyloidosis associated with dialysis: a report of five cases. J Bone Joint Surg Am 1990;72:568–74.
- Schiffl H. Impact of advanced dialysis technology on the prevalence of dialysis-related amyloidosis in long-term maintenance dialysis patients. Hemodial Int 2014;18:136–41.

Gabriel Ştefan, MD, PhD Dimona Stancu, MD, PhD "Dr. Carol Davila" Teaching Hospital of Nephrology and "Carol Davila" University of Medicine and Pharmacy Bucharest, Romania